Tirzepatide

Mechanism

Combines GLP-1 satiety/gastric-delay signaling with GIP insulinotropic effects.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Weight loss
• Glycemic control
• OSA improvement context

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

approximately 5 days (human, SC) — study. MOUNJARO FDA prescribing information, section 12.3.

Storage

Reconstituted: Solution (not lyophilized). 2-8C; may be stored at up to 30C for max 21 days; do not freeze. — source. FDA label, Mounjaro.

In sport (WADA 2026)

Not prohibited. Approved medicine. Markers of tirzepatide added to the Monitoring Program from 1 January 2026. the list

The half-life on file is 5 d, measured subcutaneously. On the schedule this record states — weekly — each dose is still at 38% of its own peak when the next is given, so the doses overlap: the peaks build to 1.61× the first.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Nausea

  Very common (>10%)onset: Dose escalationreported reversible

• Diarrhea

  Common (1-10%)onset: First weeksreported reversible

• Decreased appetite

  Very common (>10%)onset: Ongoing — intended effectreported reversible

• Vomiting

  Common (1-10%)onset: Dose escalationreported reversible

Literature on file 5

• human RCT
  Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (N Engl J Med 2025) graded on: participants were randomly assigned — read from the indexed abstract — “randomly assigned”
• review or editorial
  Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials (Curr Obes Rep 2024) graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• human RCT
  Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine 2022, cited 3354x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (New England Journal of Medicine 2021, cited 1881x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  FDA approval NDA215866, NDA217806 graded on: an FDA approval (NDA215866, NDA217806), which requires adequate and well-controlled human investigations — “NDA215866, NDA217806”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data storage common nothing on file either way

  A 10 mg/mL reconstitution (30 mg vial plus 3 mL bacteriostatic water) is circulated as the recommended concentration, chosen so every titration step reads as a round insulin-unit number.

  30mg tirzepatide + 3mL BAC water = 10mg/mL (recommended concentration)

  On the record Reconstitution maths on file follows the corpus formula (mass/diluent=concentration); no record endorses a specific vial size or concentration for grey-market vials.

  Source 1 · Source 2

• unverified community data storage common contradicts the record

  Community guides state reconstituted tirzepatide is stable for 28-60 days refrigerated — the upper half of that range exceeds the 28-day beyond-use convention for BAC-water vials.

  Reconstituted tirzepatide is stable for 28-60 days when refrigerated at 36-46°F (2-8°C)

  On the record Storage on file is the FDA Mounjaro label; no stability record supports 60 days for a BAC-water reconstitution, and the house rule is a 28-day beyond-use date from first puncture.

  Source 1

• unverified community data dose ubiquitous agrees with the record

  Compounded starting doses are circulated in insulin units — typically 25 units at 10 mg/mL for the 2.5 mg start, escalating 25 units per step.

  Titration from 2.5mg to 15mg weekly

  On the record Dosing on file is 0.5-15 mg weekly; the labelled 2.5 mg start and 2.5 mg escalation steps match the record, though the unit-chart framing itself is a community artefact.

  Source 1 · Source 2

• unverified community data storage common nothing on file either way

  Guides instruct injecting the diluent slowly down the vial wall, never directly onto the powder, to protect the peptide.

  Inject BAC water very slowly, letting it trickle down, never spray directly onto the powder

  On the record Nothing on file; no stability study on file addresses reconstitution technique for tirzepatide.

  Source 1

Identity

PubChem CID 156588324 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 156588324, the identifier on this record.

Molecular weight

4813

Molecular formula

C225H348N48O68

CAS number

2023788-19-2

PubChem CID

156588324; 168009818

UniProt

P43220 & P48546 (Targets)

ChEMBL

CHEMBL4297839

InChI key

AAPYRSPHYSKGIS-MCNPHUAVSA-N

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N

InChI

InChI=1S/C225H348N48O68/c1-23-126(10)183(214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(64-50-52-88-226)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-173(288)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-174(289)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301)264-198(311)146(65-51-53-89-231-170(285)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-172(287)243-150(221(334)335)82-86-171(286)232-90-96-338-98-100-340-121-176(291)233-91-97-339-99-101-341-122-181(299)300)246-202(315)157(109-179(295)296)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-180(297)298)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-175(290)114-237-193(306)147(83-87-178(293)294)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,285)(H,232,286)(H,233,291)(H,235,288)(H,236,302)(H,237,306)(H,238,307)(H,239,289)(H,240,308)(H,241,326)(H,242,327)(H,243,287)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,290)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1

Classified as

Incretin Signalingpathway

Almost every compound sold as a GLP-1 acts somewhere on this pathway, and the real differences between them, one receptor or two, how long they last, how they are cleared, sit here rather than in the trade name.

Glucose Homeostasispathway

The readings a record may cite cover different windows: a fasting glucose is one moment, HbA1c reflects roughly the previous three months, a continuous monitor's average is neither. Comparing across them is a common error.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• Tirzepatide
• tirz
• glp 2 tz
• sp 2tz
• glp 2 t box of 10
• tirz 2
• zbp 2 trz
• tirz glp 2
• glp 2 “t”
• glp 2 t – in large capacity vial lyophilized powder
• ro 2tz

Listed prices 250

What 75 shops we track listed for Tirzepatide, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record